Cardiac resynchronization therapy: need to synchronize patients and device longevities with comorbidities

Giuseppe Boriani¹, Marco Vitolo¹, Valentina Kutyifa^{2

3}

Affiliations

¹ Division of Cardiology, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Policlinico di Modena, Modena, Italy.
² Clinical Cardiovascular Research Center, University of Rochester Medical Center, 265 Crittenden Blvd., Box 653, Rochester, NY, USA.
³ Department of Cardiology, Heart Center, Semmelweis University, Budapest, Hungary.

Comment

Giuseppe Boriani et al. Europace. 2019.

. 2019 May 1;21(5):683-685.

doi: 10.1093/europace/euy297.

Giuseppe Boriani¹, Marco Vitolo¹, Valentina Kutyifa^{2

3}

¹ Division of Cardiology, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Policlinico di Modena, Modena, Italy.
² Clinical Cardiovascular Research Center, University of Rochester Medical Center, 265 Crittenden Blvd., Box 653, Rochester, NY, USA.
³ Department of Cardiology, Heart Center, Semmelweis University, Budapest, Hungary.

No abstract available

Comment on

Survival after cardiac resynchronization therapy: results from 50 084 implantations.
Leyva F, Zegard A, Okafor O, de Bono J, McNulty D, Ahmed A, Marshall H, Ray D, Qiu T. Leyva F, et al. Europace. 2019 May 1;21(5):754-762. doi: 10.1093/europace/euy267. Europace. 2019. PMID: 30590500 Free PMC article.